BRIEF—Bold seeks partners for rapid development of lead drug in COVID-19

Canadian biopharma Bold Therapeutics, which is usually focused on developing anti-cancer drugs, has announced that its lead drug BOLD-100 could be a useful antiviral agent in the fight against COVID-19.

The company’s clinical and scientific capability has been built to address drug resistance in cancer. It has not prioritized interventions for COVID-19.

Therefore, recognizing the current global humanitarian need, Bold is urgently seeking expressions of interest from collaborators which have the capability and resources to enable rapid advancement of BOLD-100 in the treatment of the virus.